practiceupdate.com/C/152409...
Awhile back, someone posted a link for the above site. It requires subscription (free) but has beneficial info on afib and other heart conditions. I cannot verify the veracity of the information but it does seem professional from doctors and clinics.
Today there are two articles on PFA and Amiodarone. The following are excerpts which give a summary that may be helpful. But like all of the info we share, each individual may have different outcomes.
Info that you may want to discuss with your doctor.
At 24 European centers (77 operators) pulsed field ablation was performed in 1568 patients with AF: age 64.5±11.5 years, female 35%, paroxysmal/persistent AF 65%/32%, CHA2DS2-VASc 2.2±1.6, median left ventricular ejection fraction 60%, and left atrial diameter 42 mm. Pulmonary vein isolation was achieved in 99.2% of patients. After a median (interquartile range) follow-up of 367 (289-421) days, the 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was 78.1% (95% CI, 76.0%-80.0%); clinical effectiveness was more common in patients with paroxysmal AF versus persistent AF (81.6% versus 71.5%; P=0.001). Acute major adverse events occurred in 1.9% of patients.
Risk up with amiodarone versus flecainide or sotalol among seniors with atrial fibrillation receiving apixaban or rivaroxaban
For patients with atrial fibrillation receiving apixaban or rivaroxaban, the risk of bleeding-related hospitalizations is greater during amiodarone treatment than flecainide or sotalol, according to a study published online May 22 in the Annals of Internal Medicine.